The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease

Experimental Neurology
Joanne E NashJonathan Brotchie

Abstract

In Parkinson's disease (PD), degeneration of the dopaminergic nigrostriatal pathway leads to enhanced transmission at NMDA receptors containing NR2B subunits. Previous studies have shown that some, but not all, NR2B-containing NMDA receptor antagonists alleviate parkinsonian symptoms in animal models of PD. Furthermore, enhanced NMDA receptor-mediated transmission underlies the generation of L-DOPA-induced dyskinesia (LID). The subunit content of NMDA receptors responsible for LID is not clear. Here, we assess the actions of the NMDA antagonist CP-101,606 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson's disease. CP-101,606 is selective for NMDA receptors containing NR2B subunits, with higher affinity for NR1/NR2B complexes compared to ternary NR1/NR2A/NR2B complexes. CP-101,606 had no significant effect on parkinsonian symptoms when administered as monotherapy over a range of doses (0.1-10 mg/kg). CP-101,606 provided a modest potentiation of the anti-parkinsonian actions of L-DOPA (8 mg/kg), although, at doses of 1 and 3 mg/kg, CP-101,606 exacerbated LID. Results of this study provide further evidence of differences in the anti-parkinsonian activity and effects on LID of the NR2B...Continue Reading

References

Nov 1, 1992·Neuroreport·F B WeihmullerJ F Marshall
Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·J B Penney, A B Young
Jan 1, 1993·Journal of Neural Transmission. General Section·J T Greenamyre
Apr 19, 1996·The Journal of Biological Chemistry·M J GallagherD R Lynch
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·J C BrimecombeE Aizenman
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Aug 3, 2001·Nature Reviews. Neuroscience·E BezardC E Gross
Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frédéric CalonThérèse Di Paolo
Jul 12, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Joanne E Nash, Jonathan M Brotchie
Oct 31, 2002·Nature Neuroscience·John A Kemp, Ruth M McKernan
Apr 30, 2003·Journal of Neurochemistry·Anthone W Dunah, David G Standaert

❮ Previous
Next ❯

Citations

Oct 4, 2006·Nature Reviews. Drug Discovery·Anthony H V SchapiraGiora Davidai
Jul 12, 2011·Brain : a Journal of Neurology·Ying-Zu HuangRou-Shayn Chen
Apr 10, 2009·The Journal of Pharmacology and Experimental Therapeutics·Daniella RylanderM Angela Cenci
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Albert Y Hung, Michael A Schwarzschild
Feb 22, 2014·Journal of Neural Transmission·Clare Finlay, Susan Duty
Dec 3, 2008·Expert Opinion on Emerging Drugs·Karl Strecker, Johannes Schwarz
May 2, 2015·Journal of Neurosurgery·Vincent A JourdainThérèse Di Paolo
Dec 3, 2014·Current Opinion in Pharmacology·Fabrizio Gardoni, Monica Di Luca
Mar 14, 2007·Neurobiology of Aging·Pershia SamadiThérèse Di Paolo
May 26, 2017·Expert Opinion on Investigational Drugs·Silvia CerriFabio Blandini
Aug 26, 2017·Molecular Neurobiology·Sara Sanz-BlascoJuan E Ferrario
Feb 2, 2018·Journal of Neural Transmission·Manuela Mellone, Fabrizio Gardoni
Mar 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Jordi Gomez-RamirezJonathan M Brotchie
Feb 22, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Uriel Heresco-LevyDaniel C Javitt
Feb 19, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Antonio PisaniPaolo Calabresi
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Paolo CalabresiBarbara Picconi
Jul 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Jonathan M Brotchie
Aug 21, 2008·Nature Reviews. Neuroscience·Peter Jenner
Apr 12, 2019·Biomolecules·Fabio Del BelloWilma Quaglia
Mar 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Nicolas VeyresPhilippe Huot
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie
May 17, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mario van der SteltJonathan M Brotchie
Nov 3, 2016·European Journal of Pain : EJP·M Azqueta-GavaldonE Kraft
Mar 13, 2014·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Florian Müller-Dahlhaus, Ulf Ziemann
Sep 2, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·John G NuttJaren W Landen
Dec 28, 2015·Tissue Engineering and Regenerative Medicine·Jun-Won YunByeong-Cheol Kang
Jul 8, 2019·Neurobiology of Disease·Anthony M DownsPaola Bonsi
Dec 23, 2020·Parkinsonism & Related Disorders·Annalisa PinnaMicaela Morelli
Aug 25, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xin-Shi WangCheng-Long Xie
Aug 28, 2021·International Journal of Molecular Sciences·Abdallah AhnaouWilhelmus H Drinkenburg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.